CN100362986C - 干粉吸入组合物 - Google Patents

干粉吸入组合物 Download PDF

Info

Publication number
CN100362986C
CN100362986C CNB038134608A CN03813460A CN100362986C CN 100362986 C CN100362986 C CN 100362986C CN B038134608 A CNB038134608 A CN B038134608A CN 03813460 A CN03813460 A CN 03813460A CN 100362986 C CN100362986 C CN 100362986C
Authority
CN
China
Prior art keywords
dry powder
pharmaceutical composition
powder pharmaceutical
cellobiose
acetates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038134608A
Other languages
English (en)
Chinese (zh)
Other versions
CN1658837A (zh
Inventor
T·C·罗彻
P·A·布伊萨拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1658837A publication Critical patent/CN1658837A/zh
Application granted granted Critical
Publication of CN100362986C publication Critical patent/CN100362986C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038134608A 2002-04-13 2003-04-10 干粉吸入组合物 Expired - Fee Related CN100362986C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0208609.8 2002-04-13
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Publications (2)

Publication Number Publication Date
CN1658837A CN1658837A (zh) 2005-08-24
CN100362986C true CN100362986C (zh) 2008-01-23

Family

ID=9934856

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038134608A Expired - Fee Related CN100362986C (zh) 2002-04-13 2003-04-10 干粉吸入组合物

Country Status (19)

Country Link
US (2) US20050232998A1 (https=)
EP (1) EP1509199A1 (https=)
JP (1) JP2005529874A (https=)
KR (1) KR20040097348A (https=)
CN (1) CN100362986C (https=)
AR (1) AR039408A1 (https=)
AU (1) AU2003224278A1 (https=)
BR (1) BR0309115A (https=)
CA (1) CA2482249A1 (https=)
GB (1) GB0208609D0 (https=)
IL (1) IL164421A0 (https=)
IS (1) IS7501A (https=)
MX (1) MXPA04010082A (https=)
NO (1) NO20044496L (https=)
PL (1) PL373293A1 (https=)
RU (1) RU2004130438A (https=)
TW (1) TW200407174A (https=)
WO (1) WO2003088944A1 (https=)
ZA (1) ZA200408247B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
JP2009513531A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
WO2006086270A1 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
WO2009031011A2 (en) * 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2874928B1 (en) 2012-07-19 2016-06-15 Adamis Pharmaceuticals Corporation Powder feeding apparatus
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
ES2942297T3 (es) * 2014-07-31 2023-05-31 Vectura Inc Formulaciones de polvo seco para inhalación
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416951A1 (en) * 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments comprising salmeterol and fluticason
WO1999033853A2 (en) * 1997-12-23 1999-07-08 Quadrant Holdings Cambridge Limited Carbohydrates, useful in solid delivery systems
WO2002015876A2 (en) * 2000-08-21 2002-02-28 Quadrant Healthcare (Uk) Limited Amorphous carrier materials for drug delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
DE3682457D1 (de) * 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK0994887T3 (da) * 1997-07-03 2003-03-17 Elan Drug Delivery Ltd Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416951A1 (en) * 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments comprising salmeterol and fluticason
WO1999033853A2 (en) * 1997-12-23 1999-07-08 Quadrant Holdings Cambridge Limited Carbohydrates, useful in solid delivery systems
WO2002015876A2 (en) * 2000-08-21 2002-02-28 Quadrant Healthcare (Uk) Limited Amorphous carrier materials for drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法

Also Published As

Publication number Publication date
GB0208609D0 (en) 2002-05-22
JP2005529874A (ja) 2005-10-06
US20080060645A1 (en) 2008-03-13
AU2003224278A1 (en) 2003-11-03
NO20044496L (no) 2004-11-15
ZA200408247B (en) 2006-03-29
CN1658837A (zh) 2005-08-24
AR039408A1 (es) 2005-02-16
EP1509199A1 (en) 2005-03-02
RU2004130438A (ru) 2005-06-10
CA2482249A1 (en) 2003-10-30
US20050232998A1 (en) 2005-10-20
TW200407174A (en) 2004-05-16
MXPA04010082A (es) 2004-12-13
BR0309115A (pt) 2005-02-01
KR20040097348A (ko) 2004-11-17
PL373293A1 (en) 2005-08-22
WO2003088944A1 (en) 2003-10-30
IS7501A (is) 2004-10-11
IL164421A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CN100362986C (zh) 干粉吸入组合物
CN1150895C (zh) 用于吸入给药的干粉
EP3111926B1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
US9549936B2 (en) Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide
US20020076382A1 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
CZ288146B6 (en) Pharmaceutical aerosol preparation, process of its preparation and use
AU2008325290B2 (en) Dry powder formulations comprising ascorbic acid derivates
CN107205936A (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
CA2538419C (en) Use of ciclesonide for the treatment of respiratory diseases
EP4188327B1 (en) Combination therapy for inhalation administration
KR20040099436A (ko) 건조 분말 조성물
US20090246281A1 (en) Soft steroid compositions for use in dry powder inhalers
RU2470639C2 (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
WO2004093914A1 (en) Formulations for treatment of pulmonary disorders comprising a bronchodilator, a vasoconstrictor and a corticosteroid
TR2022006361A2 (tr) İnhalasyona uygun kompozi̇syonlar
TR2022006358A2 (tr) Korti̇kosteroi̇d ve beta-2 agoni̇st i̇çeren kompozi̇syonlar
HK1228796B (en) Compositions, methods & systems for respiratory delivery of two or more active agents
TW201618759A (zh) 具有經改善之組合型活性成分之穩定性的吸入型調配物乾粉末
HK1228796A (en) Compositions, methods & systems for respiratory delivery of two or more active agents
HK1228796A1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
MXPA06004984A (en) Soft steroid compositions for use in dry powder inhalers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080123